Clinical Trial Update: Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids [Phase 3]

View source ↗

Summary

Phase 3 trial of ATG-Fresenius after renal transplantation without corticosteroids was terminated. The update reports on the efficacy and safety observations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Rejection

Drugs mentioned

• ATG-Fresenius (anti-thymocyte globulin)

Snippet

Sponsor: Neovii Biotech | Conditions: Renal Transplant Rejection | Phase 3 | Status: TERMINATED